

Nutritional Evaluation and Optimisation in Neonates

| | | |
|--|---|---|
| Submission date 28/10/2009 | Recruitment status No longer recruiting | <input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol |
| Registration date 25/11/2009 | Overall study status Completed | <input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results |
| Last Edited 04/05/2016 | Condition category Pregnancy and Childbirth | <input type="checkbox"/> Individual participant data |

Plain English summary of protocol
Not provided at time of registration

Study website
<http://www.rbht.nhs.uk/research/cteu/projects/neonatal-medicine/neon/>

Contact information

Type(s)
Scientific

Contact name
Dr Sabita Uthaya

Contact details
Chelsea and Westminster Hospital
3rd Floor
Lift bank B
369 Fulham Road
London
United Kingdom
SW10 9NH

Additional identifiers

EudraCT/CTIS number
2009-016731-34

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

EME 08/99/04; CRO1413

Study information

Scientific Title

Amino acid regimen and intravenous lipid composition in preterm parenteral nutrition: a randomised controlled trial of Nutritional Evaluation and Optimisation in Neonates

Acronym

NEON

Study objectives

Introduction of recommended daily intake (RDI) of amino acids will lead to an increase in non-adipose (lean) body mass; administration of SMOFLIPID® will reduce intrahepatocellular lipid content (IHCL) in preterm babies at term age equivalent.

Link to EME project website: <http://www.eme.ac.uk/projectfiles/089904info.pdf>
Protocol can be found at: <http://www.eme.ac.uk/projectfiles/089904protocol.pdf>

Ethics approval required

Old ethics approval format

Ethics approval(s)

Hammersmith Research Ethics Committee, 08/12/2009

Study design

Multicentre randomised 2 x 2 factorial double-blind controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Preterm birth

Interventions

Eligible preterm infants will be randomised by 24 hours of age (previously 12 hours of age, updated 02/07/2013) to receive:

1. Either incremental amino acids in parenteral nutrition or the RDI of amino acids from day one, and
2. Either 20% intralipid or 20% SMOFLIPID®

There will be four groups:

Group 1: incremental amino acid and 20% intralipid

Group 2: incremental amino acid and 20% SMOFLIPID®

Group 3: RDI of amino acids and 20% intralipid

Group 4: RDI of amino acids and 20% SMOFLIPID®

Infants will be followed from birth and until they reach 37 - 44 weeks corrected age at which point the final study assessment (magnetic resonance imaging [MRI] scan) takes place.

Intervention Type

Supplement

Primary outcome measure

1. For the amino acid intervention: non-adipose (lean) body mass measured by whole body MRI at term age equivalent
2. For the lipid intervention: hepatic magnetic resonance spectroscopy (MRS) to measure IHCL at term age equivalent

Secondary outcome measures

1. Anthropometry (weight, length and head circumference) measured at term age equivalent
2. Brain MRI (brain volumes, white matter apparent diffusion co-efficient values, cerebral vessel tortuosity) measured at term age equivalent
3. Metabolic index of insulin resistance at term age equivalent (quantitative insulin-sensitivity check index [QUICKI]), calculated using fasting serum glucose and insulin

Added 07/12/2009:

4. Ratio of internal to subcutaneous adipose tissue at term age equivalent.
5. Serum triglyceride and serum bilirubin levels.

Added 11/05/2010:

6. Metabonomic profile
7. Incidence of death
8. Number of infants with incomplete follow-up

Added 24/03/2011:

9. Inflammatory markers and lipid profile

Overall study start date

20/05/2010

Completion date

31/12/2013

Eligibility

Key inclusion criteria

1. Preterm infants (either sex) born below 31 weeks of gestation (defined as less than or equal to 30 weeks and 6 days)
2. Written informed consent from parents

Participant type(s)

Patient

Age group

Neonate

Sex

Both

Target number of participants

160 infants

Key exclusion criteria

1. Major congenital or life threatening abnormalities
2. Inability to randomise in time to allow administration of trial parenteral nutrition (PN) within 24 hours of birth

Date of first enrolment

20/05/2010

Date of final enrolment

31/12/2013

Locations**Countries of recruitment**

England

United Kingdom

Study participating centre

Chelsea and Westminster Hospital

London

United Kingdom

SW10 9NH

Sponsor information**Organisation**

Imperial College London (UK)

Sponsor details

South Kensington
London
England
United Kingdom
SW7 2AZ

Sponsor type

University/education

Website

<http://www3.imperial.ac.uk/>

ROR

<https://ror.org/041kmwe10>

Funder(s)**Funder type**

Government

Funder Name

Medical Research Council (MRC)/National Institutes of Health Research (NIHR) (UK) - Efficacy and Mechanism Evaluation (EME) Programme (ref: EME 08/99/04)

Results and Publications**Publication and dissemination plan**

Not provided at time of registration

Intention to publish date**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration

Study outputs

| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---------------------------------|---------|--------------|------------|----------------|-----------------|
| Results article | results | 01/03/2016 | | Yes | No |
| Results article | results | 01/06/2016 | | Yes | No |